Hedera Dx is on a mission to make modern cancer care accessible worldwide by enabling hospital laboratories to run advanced, in-house next-generation sequencing (NGS) testing. We provide clinically actionable tumor profiling solutions — including FFPE, ctDNA (liquid biopsy) and RNA assays — together with reporting software that links tumor profiles to regulatory-approved therapy options.

We deliver streamlined, CE‑IVDR aligned NGS workflows that integrate into existing molecular pathology labs. Our solution supports both tissue and liquid biopsies across the patient journey, simplifying sample processing, sequencing, reporting and therapy selection. We also offer patient-facing tools (myHedera) and analytics to support clinical decision-making.

Hedera Dx builds a decentralized clinico-genomic network to generate real-world evidence (RWE) that accelerates precision oncology and drug development. We run clinical validation and utility studies (e.g., EMPATHY NSCLC) and collaborate with hospitals, biopharma and research partners to enable evidence-driven care and innovation.